Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Effects of vilazodone on suicidal ideation and behavior in adults with major depressive disorder or generalized anxiety disorder: post-hoc analysis of randomized, double-blind, placebo-controlled trials

Open access
Thase, Michael E., Edwards, John, Durgam, Suresh, Chen, Changzheng, Chang, Cheng-Tao, Mathews, Maju, Gommoll, Carl P. · 2017 · International Clinical Psychopharmacology

Abstract

Treatment-emergent suicidal ideation and behavior are ongoing concerns with antidepressants. Vilazodone, currently approved for the treatment of major depressive disorder (MDD) in adults, has also been evaluated in generalized anxiety disorder (GAD). Post-hoc analyses of vilazodone trials were carried out to examine its effects on suicidal ideation and behavior in adults with MDD or GAD. Data were pooled from vilazodone trials in MDD (four studies) and GAD (three studies). The incidence of suicide-related events was analyzed on the basis of treatment-emergent adverse event reporting and Columbia-Suicide Severity Rating Scale (C-SSRS) monitoring. Treatment-emergent suicidal ideation was analyzed on the basis of a C-SSRS category shift from no suicidal ideation/behavior (C-SSRS=0) at baseline to suicide ideation (C-SSRS=1-5) during treatment. In pooled safety populations (MDD, n=2233; GAD, n=1475), suicide-related treatment-emergent adverse events occurred in less than 1% of vilazodone-treated and placebo-treated patients. Incidences of C-SSRS suicidal ideation were as follows: MDD (vilazodone=19.9%, placebo=24.7%); GAD (vilazodone=7.7%, placebo=9.4%). Shifts from no suicidal ideation/behavior at baseline to suicidal ideation during treatment were as follows: MDD (vilazodone=9.4%, placebo=10.3%); GAD (vilazodone=4.4%, placebo=6.1%). Data from placebo-controlled studies indicate little or no risk of treatment-emergent suicidal ideation or behavior with vilazodone in adults with MDD or GAD. Nevertheless, all patients should be monitored for suicidal thoughts and behaviors during antidepressant treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/yic.0000000000000180

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Overall suicidality and suicidal behavior in younger and older adults. Analyzed in patients from the pooled safety population who had at least one available postbaseline C-SSRS assessment, with incidence on the basis of each patient’s maximum C-SSRS score during double-blind treatment. Overall suicidality (a) was defined as an endorsement of any suicidal ideation or behavior category (maximum C-SSRS score of 1–10). Suicidal behavior (b) was defined as an endorsement of any suicidal behavior category (maximum C-SSRS score of 6–10). CI, confidence interval; C-SSRS, Columbia-Suicide Severity Rating Scale; GAD, generalized anxiety disorder; MDD, major depressive disorder; OR, odds ratio; VLZ, vilazodone.
Fig. 1 Overall suicidality and suicidal behavior in younger and older adults. Analyzed in patients from the pooled safety population who had at least one available postbaseline C-SSRS assessment, with incidence on the basis of each patient’s maximum C-SSRS score during double-blind treatment. Overall suicidality (a) was defined as an endorsement of any suicidal ideation or behavior category (maximum C-SSRS score of 1–10). Suicidal behavior (b) was defined as an endorsement of any suicidal behavior category (maximum C-SSRS score of 6–10). CI, confidence interval; C-SSRS, Columbia-Suicide Severity Rating Scale; GAD, generalized anxiety disorder; MDD, major depressive disorder; OR, odds ratio; VLZ, vilazodone.CC BY-NC-ND · PubMed Central
Fig. 2 Incidence of C-SSRS suicidal ideation by visit (long-term major depressive disorder study population). All patients in this study were treated with open-label vilazodone. Analysis carried out in patients who had an available C-SSRS assessment at the relevant study visit. No patient was counted more than once per study visit. C-SSRS, Columbia-Suicide Severity Rating Scale; Wk, week.
Fig. 2 Incidence of C-SSRS suicidal ideation by visit (long-term major depressive disorder study population). All patients in this study were treated with open-label vilazodone. Analysis carried out in patients who had an available C-SSRS assessment at the relevant study visit. No patient was counted more than once per study visit. C-SSRS, Columbia-Suicide Severity Rating Scale; Wk, week.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Cited by

See all 12

Metadata

Authors
Thase, M. E., Edwards, J., Durgam, S., Chen, C., Chang, C.-T., Mathews, M., & Gommoll, C. P.
Affiliations
Allergan (United States) (US)
Corresponding author
Thase, Michael E.
Venue
International Clinical Psychopharmacology
Published
2017-09
Volume
32
Issue
5
Pages
281-288
ISSN
0268-1315 (ISSN-L)
OpenAlex
W2616544698
Cited by
11
References
24
Citations by year
2024: 1 · 2023: 1 · 2022: 1 · 2021: 2 · 2020: 2 · 2019: 3 · 2018: 1
FWCI
2.03
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • International Clinical Psychopharmacology (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • Forest Research Institute
  • Allergan
Topics
  • Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
Keywords
vilazodone, suicidal ideation, suicidal behavior, major depressive disorder, generalized anxiety disorder, antidepressant safety, treatment-emergent adverse events, Columbia Suicide Severity Rating Scale, serotonin reuptake inhibitors
MeSH terms
Vilazodone Hydrochloride, Adult, Anxiety Disorders, Major Depressive Disorder, Double-Blind Method, Female, Humans, Male, Suicide, Attempted, Randomized Controlled Trials as Topic, Selective Serotonin Reuptake Inhibitors, Young Adult, Suicidal Ideation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of vilazodone on suicidal ideation and behavior in adults with major depressive disorder or generalized anxiety disorder: post-hoc analysis of randomized, double-blind, placebo-controlled trials. https://app.cochat.ai/papers/10.1097/yic.0000000000000180
The paper
Thase, M. E., Edwards, J., Durgam, S., Chen, C., Chang, C.-T., Mathews, M., & Gommoll, C. P. (2017). Effects of vilazodone on suicidal ideation and behavior in adults with major depressive disorder or generalized anxiety disorder: post-hoc analysis of randomized, double-blind, placebo-controlled trials. International Clinical Psychopharmacology. https://doi.org/10.1097/yic.0000000000000180

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.